ArticleExperimental and therapeutic medicine2022
Application and evaluation of sacubitril/valsartan in patients with cardiac insufficiency during perioperative period of cardiac surgery.
Article in Experimental and therapeutic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Impacts of Sacubitril-Valsartan versus Valsartan on Left Ventricular Remodeling and Cardiac Function in Patients with Ischemic Heart Failure and Reduced Ejection Fraction: A Randomized Double-blinded Controlled Trial.Cardiovascular & hematological disorders drug targets · 2026Trial
- Changes in Cardiac Functional Parameters After Discontinuation of Sacubitril/Valsartan in Hemodialysis Patients: Insights From Left Ventricular End-Diastolic Diameter in Real-World Observational Data.Hemodialysis international. International Symposium on Home Hemodialysis · 2026Observational
- Determining optimal pretreatment in cardiac surgery: an experimental study.General thoracic and cardiovascular surgery · 2025Article
- Perioperative utilization of angiotensin receptor-neprilysin inhibitor in patients with heart failure with reduced ejection fraction undergoing coronary artery bypass grafting-a narrative review.Indian journal of thoracic and cardiovascular surgery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sacubitril/valsartan is the first angiotensin II receptor blocker neprilysin inhibitor, which inhibits both angiotensin II receptor and neprilysin. In recent years, a series of clinical studies have shown that sacubitril/valsartan has a good therapeutic effect on heart failure. The present study was conducted to investigate the therapeutic effect and safety of sacubitril/valsartan in patients with cardiac insufficiency during the perioperative period of cardiac surgery. A total of 59 patients were divided into two groups: Heart failure with reduced ejection fraction (HFrEF) group and heart failure with preserved ejection fraction (HFpEF) group. The therapeutic effect on patients with sacubitril/valsartan was assessed by the values of left ventricular ejection fraction (LVEF) and left ventricular end-diastolic diameter (LVED). The renal safety of patients was assessed by serum creatinine (Cr) and blood urea nitrogen (BUN). Sacubitril/valsartan decreased LVED in HFrEF group and HFpEF group. And it showed a significant increase of LVEF in the HFrEF group. There was no significant change in Cr and BUN. Sacubitril/valsartan showed a good therapeutic effect on cardiac function for the perioperative period of cardiac surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.